1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

  • June 2016
  • -
  • GlobalData
  • -
  • 43 pages

Summary

Table of Contents

Search Inside

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

Summary

Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, being responsible for approximately 90% of all cases in adults. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension, night sweats, and a general feeling of being unwell. Kidney cancer is among the 10 most frequently occurring cancers in Western countries. Globally, about 270,000 cases of kidney cancer are diagnosed yearly, and 116,000 people die from the disease.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of RCC in the 8MM, from 190,147 diagnosed incident cases in 2013 to 309,734 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 6.29% during the forecast period. In 2023, urban China will have the highest number of diagnosed incident cases of RCC in the 8MM, with 147,457 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of RCC, with 7,591 diagnosed incident cases. Similarly, as shown in the second figure below, the five-year diagnosed prevalent cases of RCC in the 8MM will increase from 600,261 diagnosed prevalent cases in 2013 to 966,190 diagnosed prevalent cases in 2023, with an AGR of 6.10% during the forecast period. The increase in the diagnosed five-year prevalent cases of RCC is partly attributed to the rising trend in the incidence rate of RCC in the 8MM, combined with changes in the population demographics in the respective markets.The rising trend in the incidence of RCC may partly be a result of increased use of imaging techniques that can detect asymptomatic tumors.

Scope

- The Renal cell carcinoma (RCC) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for RCC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC, segmented by age (at 20-year intervals, starting at age 20 years and ending at ages =80 years) and sex. It also includes a forecast of the five-year diagnosed prevalent cases of RCC in the 8MM. Additionally, it provides the RCC diagnosed incident cases, segmented by the stage at diagnosis, for the 8MM.
- The RCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The RCC EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RCC market.
- Quantify patient populations in the global RCC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RCC therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Renal cell carcinoma- Market Insights, Epidemiology and Market Forecast-2023

Renal cell carcinoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Global Kidney Cancer Therapeutics & Diagnostics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

Global Kidney Cancer Therapeutics & Diagnostics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The frequency of kidney cancer, worldwide, has increased in the recent years. Changes in lifestyle, excessive smoking, increased consumption of alcohol and a rise in obesity because of sedentary life routines ...

North America Kidney Cancer Therapeutics & Diagnostics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

North America Kidney Cancer Therapeutics & Diagnostics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

  • $ 3850
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The frequency of kidney cancer, worldwide, has increased in the recent years. Changes in lifestyle, excessive smoking, increased consumption of alcohol and a rise in obesity because of sedentary life routines ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.